ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview

ProQR Therapeutics NV

01/05/2023 13:13

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 3
(estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
6.6% increase in revenue to €1.315 million from €1.23 million a
year ago, according to the mean estimate from 5 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 4.9%
in the last three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $5​, above​ its last closing price of $2.18.
​​​

Previous quarterly performance (using preferred earnings measure
in euros). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.17       -0.16      -0.16     Met     2
 Sep. 30 2022  -0.19       -0.21      -0.34     Missed  -62
 Jun. 30 2022  -0.22       -0.22      -0.21     Beat    2.7​
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15.1
 ​​Dec.        -0.18       -0.19      -0.26     Missed  -40
 31 2021                                                
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3​
 Jun. 30 2021  -0.22       -0.24      -0.24     Met     -1.2
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1
 This summary was machine generated May 1 at 12:13 GMT.  All
figures in euros  unless otherwise stated